This analysis examines the historical and forecast performance for Sandoz in the generic pharmaceutical sector. The profile encompasses global company strategy, generic and biosimilar portfolio and pipeline analysis and assessment of financial performance. An interactive data and analysis tool provides quantitative and qualitative information.
Scope
Highlights
Reasons to Purchase
Benchmark Sandozs performance against key rivals in the generic pharmaceutical sector Evaluate Sandozs historical and forecast generic growth drivers and resistors Understand the strategy behind Sandozs recent launch of its first biosimilar, Omnitrope
